fbpx

ISOL:CSE



ISOL CSE:ISOL

Isodiol International Inc.


 

Company Description

Isodiol International Inc. (“Isodiol”) is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products. Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products. Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.

 

Officers and Executives

Name Title
Mr. Amandeep Parmar Chairman
Mr. Marcos Agramont Chief Executive Officer and Director
Mr. Bryan E. Loree Chief Financial Officer and Director
Mr. Soheil Samimi Director
Ms. Dianne Marie Szigety Secretary

 

Key Data

Valuation

Price to Sales Ratio 13.69
Price to Book Ratio 4.64
Enterprise Value to EBITDA -59.76
Enterprise Value to Sales 14.93
Total Debt to Enterprise Value 0.06

 

Efficiency

Receivables Turnover 3.29
Total Asset Turnover 0.26

 

Liquidity

Current Ratio 3.62
Quick Ratio 2.47
Cash Ratio 1.91

Profitability

Gross Margin 35.60
Operating Margin -970.05
Pretax Margin -1,204.15
Net Margin -1,204.15
Return on Assets -310.12
Return on Equity -737.96
Return on Total Capital -365.31
Return on Invested Capital -737.96

 

Capital Structure

Total Debt to Total Equity 13.13
Total Debt to Total Capital 11.60
Total Debt to Total Assets 10.97

 

CSE Filings

CSE Form 7 – Monthly Progress Report for February 2018
December 31, 2017
December 31, 2017
CSE Form 7 – Monthly Progress Report for January 2018
FORM 9

 


 

 

 

Key Highlights

Revenue $355,959
Net Income $-4.29M
2017 Sales Growth 2020.7%

 

 

 

Online Brokerages